ClinicalTrials.gg
CompletedNCT02914522SELECTIONUpdated Apr 21, 2021Results posted

Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis

A Phase 3 interventional study of Filgotinib and PTM filgotinib in Ulcerative Colitis, sponsored by Gilead Sciences. Completed at 343 sites in 40 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-04-21.

Sponsored by Gilead Sciences · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,351
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 615 studies in Colitis, Ulcerative with a site in United States — 116 open to participants now, 167 under way, 34 of them phase 3. Colitis, Ulcerative · United States.

Enrollment
10th of 499
1,351 · median 76
Started
2016
with 26 others
Phase 3
116 of 615
15 open now
Registered
266th of 615
by date

Among the 615 studies in Colitis, Ulcerative with a site in United States, this one is the 10th largest by enrollment of the 499 interventional ones that give a count, is one of 27 that started in 2016, is one of 116 in phase 3, and was the 266th registered.

Colitis, Ulcerative

1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.

Browse Colitis, Ulcerative studies →

Open to participants now

116 of the 615 studies in Colitis, Ulcerative with a site in United States are open now. Recruiting first, the newest first:

111 more — sign in →

All 116 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 615 studies in Colitis, Ulcerative with a site in United States, or all of them as a file.
02

Study summary

The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and biologic-experienced.

Participants who complete the study, or met protocol specified efficacy discontinuation criteria will have the option to enter a separate, long-term extension (LTE) study (Gilead Study GS-US-418-3899: NCT02914535).

03

Conditions studied

  • Ulcerative Colitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Males or non-pregnant, non-lactating females, ages 18 to 75 years, inclusive based on the date of the screening visit
  • Documented diagnosis of UC of at least 6 months AND with a minimum disease extent of 15 cm from the anal verge. Documentation should include endoscopic and histopathologic evidence of UC.
  • A surveillance colonoscopy is required at screening in individuals with a history of UC for 8 or more years, if one was not performed in the prior 24 months
  • Moderately to severely active UC
  • Previously demonstrated an inadequate clinical response, loss of response to, or intolerance to at least 1 of the following agents (depending on current country treatment recommendations/guidelines): , immunomodulators, tumor necrosis factor alpha (TNFa) antagonists, or vedolizumab

Key Exclusion Criteria:

  • Presence of Crohn's disease, indeterminate colitis, ischemic colitis, fulminant colitis, ulcerative proctitis, or toxic mega-colon
  • Active tuberculosis (TB) or history of latent TB that has not been treated
  • Use of any concomitant prohibited medications as described in the protocol

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,351 participants (actual)

Study arms

  • Experimental
    Induction Study (Cohort A): Filgotinib 200 mg

    Participants in Cohort A (biologic-naive) received filgotinib 200 milligrams (mg) and placebo-to-match (PTM) filgotinib 100 mg orally once daily for 10 weeks.

    Drug: Filgotinib · Drug: PTM filgotinib

  • Experimental
    Induction Study (Cohort A): Filgotinib 100 mg

    Participants in Cohort A (biologic-naive) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.

    Drug: Filgotinib · Drug: PTM filgotinib

  • Placebo comparator
    Induction Study (Cohort A): Placebo

    Participants in Cohort A (biologic-naive) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.

    Drug: PTM filgotinib

  • Experimental
    Induction Study (Cohort B): Filgotinib 200 mg

    Participants in Cohort B (biologic-experienced) received filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.

    Drug: Filgotinib · Drug: PTM filgotinib

  • Experimental
    Induction Study (Cohort B): Filgotinib 100 mg

    Participants in Cohort B (biologic-experienced) received filgotinib 100 mg and PTM filgotinib 200 mg orally once daily for 10 weeks.

    Drug: Filgotinib · Drug: PTM filgotinib

  • Placebo comparator
    Induction Study (Cohort B): Placebo

    Participants in Cohort B (biologic-experienced) received PTM filgotinib 200 mg and PTM filgotinib 100 mg orally once daily for 10 weeks.

    Drug: PTM filgotinib

  • Experimental
    Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg

    Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either Endoscopy/Bleeding/Stool Frequency (EBS) remission or Mayo Clinic Score (MCS) response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 200 mg and PTM filgotinib 100 mg for an additional 47 weeks (up to Week 58).

    Drug: Filgotinib · Drug: PTM filgotinib

  • Placebo comparator
    Maintenance Study: Placebo From Induction Filgotinib 200 mg

    Participants in the Filgotinib 200 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).

    Drug: PTM filgotinib

  • Experimental
    Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg

    Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive filgotinib 100 mg and PTM filgotinib 200 mg for an additional 47 weeks (up to Week 58).

    Drug: Filgotinib · Drug: PTM filgotinib

  • Placebo comparator
    Maintenance Study: Placebo From Induction Filgotinib 100 mg

    Participants in the Filgotinib 100 mg arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were rerandomized at Week 11 into the Maintenance Study to receive PTM filgotinib orally once daily for an additional 47 weeks (up to Week 58).

    Drug: PTM filgotinib

  • Placebo comparator
    Maintenance Study: Placebo From Induction Placebo

    Participants in the Placebo arm who completed the Induction Study and achieved either EBS remission or MCS response at Week 10 were re-randomized at Week 11 into the Maintenance Study to receive PTM filgotinib for an additional 47 weeks (up to Week 58).

    Drug: PTM filgotinib

Interventions

  • Tablet(s) administered orally once daily

    Also known as: GS-6034, GLPG0634

  • DrugPTM filgotinib

    Tablet(s) administered orally once daily

06

What researchers measure

Primary outcomes

  1. Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10

    EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 10

  2. Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58

    EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 58

Secondary outcomes

  1. Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10

    MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 10

  2. Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10

    Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 10

  3. Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10

    Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).

    Time frame: Week 10

  4. Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10

    MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 10

  5. Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845

    Cmax is defined as the maximum observed concentration of drug.

    Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10

  6. Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845

    Tmax is defined as the time to reach maximum observed concentration of drug.

    Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10

  7. Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984

    AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

    Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10

  8. Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984

    AUClast is defined as the concentration of drug from time zero to the last observable concentration.

    Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10

  9. Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984

    Ctau is defined as the observed drug concentration at the end of the dosing interval.

    Time frame: Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10

  10. Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58

    MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 58

  11. Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58

    Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.

    Time frame: Week 58

  12. Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58

    Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.

    Time frame: Week 58

  13. Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58

    Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

    Time frame: Week 58

  14. Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58

    Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).

    Time frame: Week 58

  15. Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58

    MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

    Time frame: Week 58

  16. Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845

    Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.

    Time frame: Week 26 (any Time) and Week 58 (predose)

07

Results

Posted Apr 21, 2021

Participant flow

Participants were enrolled at study sites in Australia, New Zealand, North America, South America, Asia and Europe. The first participant was screened on 14 November 2016. The last study visit occurred on 31 March 2020.

Induction Study: Up to Week 11
Participant flow — Induction Study: Up to Week 11
MilestoneInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Placebo
Started24527813726228614300000
Completed23525612723426212700000
Not completed10221028241600000
Withdrew: Adverse event56418141000000
Withdrew: Withdrew consent411463300000
Withdrew: Protocol violation02134200000
Withdrew: Lost to follow-up02110000000
Withdrew: Investigator's discretion00001000000
Withdrew: Non-compliance with study drug10000000000
Withdrew: Pregnancy00001000000
Withdrew: Did not receive study drug01001100000
Maintenance Study: Week 11 to Week 58
Participant flow — Maintenance Study: Week 11 to Week 58
MilestoneInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Placebo
Started000000202991799193
Completed000000150411044264
Not completed0000005258754929
Withdrew: Protocol-specified disease worsening0000003449533921
Withdrew: Adverse event000000721043
Withdrew: Protocol violation00000055301
Withdrew: Withdrew consent00000041634
Withdrew: Death00000020000
Withdrew: Investigator's discretion00000001200
Withdrew: Pregnancy00000000120
Withdrew: Non-compliance with study drug00000000010

Outcome measures

PrimaryInduction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10

EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 10
percentage of participantsInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): Placebo
Induction Study: Percentage of Participants Who Achieved Endoscopy/Bleeding/Stool Frequency (EBS) Remission at Week 1026.1 (20.4 to 31.8)19.1 (14.3 to 23.9)15.3 (8.9 to 21.7)11.5 (7.4 to 15.5)9.5 (5.9 to 13.0)4.2 (0.6 to 7.9)
Statistical analysis
  • Induction Study (Cohort A): Filgotinib 200 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.0157 · Difference in percentages: 10.8 · 95% CI 2.1 to 19.5Cochran-Mantel-Haenszel(CMH) test was stratified by concomitant use of oral, systemic corticosteroids (Yes/No) and immunomodulators (Yes/No) at Day 1.
  • Induction Study (Cohort A): Filgotinib 100 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.3379 · Difference in percentages: 3.8 · 95% CI -4.3 to 12.0CMH test was stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort B): Filgotinib 200 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.0103 · Difference in percentages: 7.2 · 95% CI 1.6 to 12.8CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
  • Induction Study (Cohort B): Filgotinib 100 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.0645 · Difference in percentages: 5.2 · 95% CI -0.0 to 10.5CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
PrimaryMaintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58

EBS remission was defined as an endoscopic subscore of 0 or 1; rectal bleeding subscore of 0; and at least a 1-point decrease in stool frequency from baseline to achieve a subscore of 0 or 1. Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration); rectal bleeding subscore range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes; stool frequency subscore range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal. Total score for EBS ranged from 0 to 9 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved EBS Remission at Week 5837.2 (30.2 to 44.2)11.2 (4.5 to 18.0)23.8 (17.2 to 30.5)13.5 (5.8 to 21.1)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = < 0.0001 · Difference in percentages: 26.0 · 95% CI 16.0 to 35.9CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.0420 · Difference in percentages: 10.4 · 95% CI -0.0 to 20.7CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryInduction Study: Percentage of Participants Who Achieved MCS Remission at Week 10

MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and physician's global assessment (PGA). The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 10
percentage of participantsInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): Placebo
Induction Study: Percentage of Participants Who Achieved MCS Remission at Week 1024.5 (18.9 to 30.1)17.0 (12.4 to 21.6)12.4 (6.5 to 18.3)9.5 (5.8 to 13.3)6.0 (3.0 to 8.9)4.2 (0.6 to 7.9)
Statistical analysis
  • Induction Study (Cohort A): Filgotinib 200 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.0053 · Difference in percentages: 12.1 · 95% CI 3.8 to 20.4CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort A): Filgotinib 100 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.2295 · Difference in percentages: 4.6 · 95% CI -3.1 to 12.2CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort B): Filgotinib 200 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.0393 · Difference in percentages: 5.3 · 95% CI -0.1 to 10.7CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
  • Induction Study (Cohort B): Filgotinib 100 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.5308 · Difference in percentages: 1.7 · 95% CI -3.1 to 6.6CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
SecondaryInduction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10

Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 10
percentage of participantsInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): Placebo
Induction Study: Percentage of Participants Who Achieved an Endoscopic Subscore of 0 at Week 1012.2 (7.9 to 16.6)5.8 (2.8 to 8.7)3.6 (0.1 to 7.2)3.4 (1.0 to 5.8)2.1 (0.3 to 3.9)2.1 (0.0 to 4.8)
Statistical analysis
  • Induction Study (Cohort A): Filgotinib 200 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.0047 · Difference in percentages: 8.6 · 95% CI 2.9 to 14.3CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort A): Filgotinib 100 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.3495 · Difference in percentages: 2.1 · 95% CI -2.6 to 6.8CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort B): Filgotinib 200 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.4269 · Difference in percentages: 1.3 · 95% CI -2.5 to 5.1CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
  • Induction Study (Cohort B): Filgotinib 100 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.9987 · Difference in percentages: -0.0 · 95% CI -3.4 to 3.4CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
SecondaryInduction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10

Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 10
percentage of participantsInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): Placebo
Induction Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 1035.1 (28.9 to 41.3)23.8 (18.6 to 29.0)16.1 (9.5 to 22.6)19.8 (14.8 to 24.9)13.7 (9.5 to 17.8)8.5 (3.5 to 13.4)
Statistical analysis
  • Induction Study (Cohort A): Filgotinib 200 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentages: 19.0 · 95% CI 9.9 to 28.2CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort A): Filgotinib 100 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.0672 · Difference in percentages: 7.8 · 95% CI -0.7 to 16.2CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1.
  • Induction Study (Cohort B): Filgotinib 200 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.0019 · Difference in percentages: 11.4 · 95% CI 4.2 to 18.6CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
  • Induction Study (Cohort B): Filgotinib 100 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.1286 · Difference in percentages: 5.2 · 95% CI -1.4 to 11.8CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
SecondaryInduction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10

MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 10
Reported as:
Number · percentage of participants
Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 10
percentage of participantsInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): Placebo
Induction Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 1012.2 (7.9 to 16.6)8.7 (5.2 to 12.2)4.4 (0.6 to 8.2)3.8 (1.3 to 6.3)2.1 (0.3 to 3.9)2.1 (0.0 to 4.8)
Statistical analysis
  • Induction Study (Cohort A): Filgotinib 200 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.0105 · Difference in percentages: 7.9 · 95% CI 1.9 to 13.8CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1
  • Induction Study (Cohort A): Filgotinib 100 mg vs Induction Study (Cohort A): Placebo · Cochran-Mantel-Haenszel · p = 0.1062 · Difference in percentages: 4.3 · 95% CI -1.0 to 9.6CMH test is stratified by concomitant use of oral, systemic corticosteroids (Yes or No) and of immunomodulators (Yes or No) at Day 1
  • Induction Study (Cohort B): Filgotinib 200 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.3084 · Difference in percentages: 1.7 · 95% CI -2.2 to 5.6CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
  • Induction Study (Cohort B): Filgotinib 100 mg vs Induction Study (Cohort B): Placebo · Cochran-Mantel-Haenszel · p = 0.9109 · Difference in percentages: -0.0 · 95% CI -3.4 to 3.4CMH was stratified by concomitant use of corticosteroids and of immunomodulators at Day 1, and number of prior exposure to biologic agent (≤1,\>1).
SecondaryInduction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845

Cmax is defined as the maximum observed concentration of drug.

Time frame:
Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Reported as:
Mean · nanograms per milliliter (ng/mL)
Induction Study: Pharmacokinetic (PK) Parameter: Cmax of Filgotinib and Its Metabolite GS-829845
nanograms per milliliter (ng/mL)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mg
Filgotinib1746.3 ± 1244.05725.1 ± 313.362283.3 ± 1012.03977.9 ± 403.51
Metabolite GS-8298453227.5 ± 1204.501812.2 ± 701.464373.3 ± 1121.582002.9 ± 598.73
SecondaryInduction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845

Tmax is defined as the time to reach maximum observed concentration of drug.

Time frame:
Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Reported as:
Median · hour (h)
Induction Study: PK Parameter: Tmax of Filgotinib and Its Metabolite GS-829845
hour (h)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mg
Filgotinib1.50 (0.75 to 2.00)0.75 (0.50 to 3.00)1.00 (0.50 to 2.25)0.57 (0.42 to 3.00)
Metabolite GS-8298453.76 (2.00 to 4.00)3.00 (1.00 to 6.00)3.02 (2.13 to 6.00)3.00 (1.03 to 6.00)
SecondaryInduction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984

AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval).

Time frame:
Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Reported as:
Mean · hour*nanograms per milliliter (h*ng/mL)
Induction Study: PK Parameter: AUCtau of Filgotinib and Its Metabolite GS-82984
hour*nanograms per milliliter (h*ng/mL)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mg
Filgotinib5501.3 ± 1956.391909.3 ± 788.136475.6 ± 1643.002492.3 ± 852.52
Metabolite GS-82984557982.0 ± 17767.5231187.9 ± 11858.7880208.6 ± 25096.5736075.6 ± 13396.86
SecondaryInduction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984

AUClast is defined as the concentration of drug from time zero to the last observable concentration.

Time frame:
Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Reported as:
Mean · h*ng/mL
Induction Study: PK Parameter: AUClast of Filgotinib and Its Metabolite GS-82984
h*ng/mLInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mg
Filgotinib5537.3 ± 1900.931881.9 ± 797.516743.1 ± 1743.682420.3 ± 837.26
Metabolite GS-82984560938.4 ± 6961.7730643.2 ± 12935.3779286.3 ± 27968.4934385.6 ± 15160.15
SecondaryInduction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984

Ctau is defined as the observed drug concentration at the end of the dosing interval.

Time frame:
Predose and at 0.5, 1, 2, 3, 4 and 6 hours postdose at a single visit between Week 2 and Week 10
Reported as:
Mean · ng/mL
Induction Study: PK Parameter: Ctau of Filgotinib and Its Metabolite GS-82984
ng/mLInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mg
Filgotinib12.0 ± 4.744.5 ± 3.6136.6 ± 79.064.1 ± 3.05
Metabolite GS-8298452050.0 ± 493.66934.8 ± 372.682581.3 ± 777.071062.8 ± 463.67
SecondaryMaintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58

MCS remission was defined as having a MCS of 2 or less and no single subscore higher than 1. The MCS was composed of subscores from endoscopy (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]), rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), and PGA. The PGA acknowledged the participant's daily recollection of abdominal discomfort and general sense of wellbeing, and other observations, such as physical findings and the participant's performance status. The PGA score ranged from 0 to 3 with higher score indicating the severe disease. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved MCS Remission at Week 5834.7 (27.8 to 41.5)9.2 (3.0 to 15.4)22.7 (16.1 to 29.2)13.5 (5.8 to 21.1)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentages: 25.5 · 95% CI 16.0 to 35.0CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.0658 · Difference in percentages: 9.2 · 95% CI -1.1 to 19.5CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58

Sustained EBS remission was defined as having achieved EBS remission at both Weeks 10 and 58.

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved Sustained EBS Remission at Week 5818.1 (12.5 to 23.7)5.1 (0.2 to 10.0)8.7 (4.2 to 13.2)7.9 (1.7 to 14.0)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = 0.0024 · Difference in percentages: 13.0 · 95% CI 5.3 to 20.6CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.7951 · Difference in percentages: 0.9 · 95% CI -7.0 to 8.7CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58

Six-month corticosteroid-free EBS remission at Week 58 was defined as achieving EBS remission with no corticosteroid use for the indication of ulcerative colitis for at least 6 months prior to Week 58.

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved 6-Month Corticosteroid-Free EBS Remission at Week 5827.2 (17.5 to 36.8)6.4 (0.0 to 14.4)13.6 (5.5 to 21.7)5.4 (0.0 to 14.0)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = 0.0055 · Difference in percentages: 20.8 · 95% CI 7.7 to 33.9CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.1265 · Difference in percentages: 8.2 · 95% CI -4.2 to 20.6CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58

Endoscopic subscore range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease (spontaneous bleeding, ulceration).

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved Endoscopic Subscore of 0 at Weeks 5815.6 (10.3 to 20.9)6.1 (0.9 to 11.4)13.4 (8.0 to 18.7)7.9 (1.7 to 14.0)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = 0.0157 · Difference in percentages: 9.5 · 95% CI 1.8 to 17.1CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.1808 · Difference in percentages: 5.5 · 95% CI -2.9 to 13.9CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58

Geboes histologic remission was assessed using the Geboes histologic scores for evaluation of disease severity in ulcerative colitis and classifies histologic changes. Remission was defined as having Grade 0 of \<= 0.3, Grade 1 of \<= 1.1, Grade 2A of \<= 2A.3, Grade 2B of 2B.0, Grade 3 of 3.0, Grade 4 of 4.0, and Grade 5 of 5.0. Possible scores are Grade 0: Architectural changes (0.0=No abnormality to 0.3=Severe diffuse or multifocal abnormalities); Grade 1: Chronic inflammatory infiltrate (1.0=No increase to 1.3=Marked increase); Grade 2A: Eosinophils in lamina propria (2A.0=No increase to 2A.3-=Marked increase; Grade 2B: Neutrophils in lamina propria (2B.0= No increase to 2B.3=Marked increase); Grade 3: Neutrophils in epithelium (3.0=None to 3.3=\>50% crypts involved); Grade 4: Crypt destruction (4.0=none to 4.3=Unequivocal crypt destruction), and Grade 5: Erosions and ulcerations: (5.0=No erosion, ulceration or granulation to 5.4=Ulcer or granulation tissue).

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved Geboes Histologic Remission at Week 5838.2 (31.2 to 45.2)13.3 (6.0 to 20.5)27.9 (20.9 to 34.9)18.0 (9.4 to 26.5)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = <0.0001 · Difference in percentages: 24.9 · 95% CI 14.6 to 35.2CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.0521 · Difference in percentages: 9.9 · 95% CI -1.3 to 21.2CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58

MCS remission (alternative definition) was defined as having rectal bleeding, stool frequency, and PGA subscores of 0 and an endoscopic subscore of 0 or 1; overall MCS of ≤ 1. MCS possible subscores: rectal bleeding (range: 0 to 3, where 0 = no blood seen and 3 = blood alone passes), stool frequency (range: 0 to 3, where 0 = normal number of stools and 3 = at least 5 stools more than normal), PGA subscore (range: 0 to 3 with higher score indicating the severe disease), and an endoscopic subscore (range: 0 to 3, where 0 = normal or inactive disease and 3 = severe disease \[spontaneous bleeding, ulceration\]. Total score for MCS ranged from 0 to 12 (sum of all subscores), with higher scores indicating more severe disease.

Time frame:
Week 58
Reported as:
Number · percentage of participants
Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 58
percentage of participantsMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mg
Maintenance Study: Percentage of Participants Who Achieved MCS Remission (Alternative Definition) at Week 5822.1 (16.1 to 28.1)6.1 (0.9 to 11.4)12.2 (7.0 to 17.4)7.9 (1.7 to 14.0)
Statistical analysis
  • Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg vs Maintenance Study: Placebo From Induction Filgotinib 200 mg · Cochran-Mantel-Haenszel · p = 0.0005 · Difference in percentages: 16.0 · 95% CI 7.8 to 24.2CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
  • Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg vs Maintenance Study: Placebo From Induction Filgotinib 100 mg · Cochran-Mantel-Haenszel · p = 0.2946 · Difference in percentages: 4.3 · 95% CI -3.9 to 12.6CMH test was stratified by concomitant use of corticosteroids and of immunomodulators at maintenance baseline; participation in Induction (A or B).
SecondaryMaintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845

Plasma concentration is defined as the measured drug concentration of filgotinib and its metabolite GS-829845. Lower limit of quantitation (LLOQ) was defined as 1 ng/mL for analyte filgotinib and 2 ng/mL for analyte GS-829845.

Time frame:
Week 26 (any Time) and Week 58 (predose)
Reported as:
Median · ng/mL
Maintenance Study: Plasma Concentration of Filgotinib and Its Metabolite GS-829845
ng/mLMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg
Filgotinib: Week 268.5 (5.0 to 25.8)4.4 (2.5 to 14.0)
Filgotinib: Week 583.9 (NA to 9.1)4.1 (NA to 6.9)
Metabolite GS-829845: Week 262495.0 (1940.0 to 3010.0)1180.0 (852.0 to 1550.0)
Metabolite GS-829845: Week 581930.0 (1320.0 to 2630.0)973.5 (773.0 to 1350.0)

Adverse events

Collected over Induction Study: first dose date up to one day before the Maintenance first dose date or last dose date whichever is earlier (maximum 17 weeks) plus 30 days, Maintenance study: First dose to the last dose in the Maintenance Study (maximum 51 weeks) plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Induction Study (Cohort A): Filgotinib 200 mg0/245 (0%)3/245 (1.2%)40/245 (16.3%)
Induction Study (Cohort A): Filgotinib 100 mg0/278 (0%)13/277 (4.7%)43/277 (15.5%)
Induction Study (Cohort A): Placebo0/137 (0%)4/137 (2.9%)20/137 (14.6%)
Induction Study (Cohort B): Filgotinib 200 mg0/262 (0%)19/262 (7.3%)83/262 (31.7%)
Induction Study (Cohort B): Filgotinib 100 mg0/286 (0%)15/285 (5.3%)77/285 (27%)
Induction Study (Cohort B): Placebo0/143 (0%)9/142 (6.3%)55/142 (38.7%)
Maintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mg2/202 (1%)9/202 (4.5%)67/202 (33.2%)
Maintenance Study: Placebo From Induction Filgotinib 200 mg0/99 (0%)0/99 (0%)33/99 (33.3%)
Maintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mg0/179 (0%)8/179 (4.5%)53/179 (29.6%)
Maintenance Study: Placebo From Induction Filgotinib 100 mg0/91 (0%)7/91 (7.7%)33/91 (36.3%)
Maintenance Study: Placebo From Induction Placebo0/93 (0%)4/93 (4.3%)26/93 (28%)
Most frequent serious events
Showing 10 of 68
Most frequent serious events
EventInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Placebo
Colitis ulcerativeGastrointestinal disorders0/2453/2773/1377/2625/2855/1420/2020/991/1791/910/93
AppendicitisInfections and infestations0/2451/2770/1370/2620/2850/1421/2020/992/1790/910/93
Iron deficiency anaemiaBlood and lymphatic system disorders0/2451/2770/1371/2620/2850/1420/2020/990/1791/910/93
Coronary artery stenosisCardiac disorders0/2450/2770/1370/2620/2850/1420/2020/990/1791/910/93
Autoimmune hepatitisHepatobiliary disorders0/2450/2770/1370/2620/2850/1420/2020/990/1791/910/93
Acute hepatitis BInfections and infestations0/2450/2770/1370/2620/2850/1420/2020/990/1791/910/93
Gastroenteritis viralInfections and infestations0/2450/2770/1371/2620/2851/1420/2020/990/1791/910/93
Meniscus injuryInjury, poisoning and procedural complications0/2450/2770/1370/2620/2850/1420/2020/990/1791/910/93
Dental cystGastrointestinal disorders0/2450/2770/1370/2620/2850/1420/2020/990/1790/911/93
Supernumerary teethGastrointestinal disorders0/2450/2770/1370/2620/2850/1420/2020/990/1790/911/93
Most frequent other events
Most frequent other events
EventInduction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboMaintenance Study: Filgotinib 200 mg From Induction Filgotinib 200 mgMaintenance Study: Placebo From Induction Filgotinib 200 mgMaintenance Study: Filgotinib 100 mg From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Filgotinib 100 mgMaintenance Study: Placebo From Induction Placebo
Colitis ulcerativeGastrointestinal disorders6/2453/2775/13714/26211/2856/14221/20218/9918/17916/9110/93
NasopharyngitisInfections and infestations7/2459/2772/13720/26220/28511/14222/2026/9912/1796/915/93
HeadacheNervous system disorders11/24512/2776/13719/26210/2859/1427/2020/9910/1795/915/93
ArthralgiaMusculoskeletal and connective tissue disorders0/2454/2772/1378/26210/2857/1428/2027/996/1793/914/93
AnaemiaBlood and lymphatic system disorders6/24510/2774/13712/26211/28510/1424/2020/994/1791/910/93
Abdominal painGastrointestinal disorders3/2453/2773/1378/2627/2859/1428/2026/996/1792/914/93
PyrexiaGeneral disorders5/2451/2771/1376/2623/2858/1426/2021/994/1793/911/93
Upper respiratory tract infectionInfections and infestations2/2452/2770/13713/2624/2855/14211/2023/996/1793/913/93
NauseaGastrointestinal disorders8/2453/2771/1377/26215/2856/1425/2021/994/1790/912/93

Baseline characteristics

Safety Analysis Set for the Induction Study (Cohorts A and B) included all participants who took at least 1 dose of study drug in the Induction Study.

Age, Categorical
Age, Categorical(Participants)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboTotal
<=18 years0000000
Between 18 and 65 years2342611292432641281259
>=65 years1116819211489
Sex: Female, Male
Sex: Female, Male(Participants)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboTotal
Female122120501149956561
Male1231578714818686787
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboTotal
Race — American Indian or Alaska Native1000001
Race — Asian777938505127322
Race — Black or African American23146319
Race — White1651929519021298952
Race — Other0220015
Race — Not Permitted01118161349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboTotal
Ethnicity — Not Hispanic or Latino2382691342492731341297
Ethnicity — Hispanic or Latino66388435
Ethnicity — Not Permitted12054416
Region of Enrollment
Region of Enrollment(Participants)Induction Study (Cohort A): Filgotinib 200 mgInduction Study (Cohort A): Filgotinib 100 mgInduction Study (Cohort A): PlaceboInduction Study (Cohort B): Filgotinib 200 mgInduction Study (Cohort B): Filgotinib 100 mgInduction Study (Cohort B): PlaceboTotal
Poland575625172211188
United States143319365821181
India554927833145
Japan15166292914109
Ukraine334624120106
France11132261980
Germany1303126970
Russia21101269159
Italy46115191257
United Kingdom7301211740
Belgium0001614636
South Korea172512532
Australia631108230
Hungary98305227
Romania33235319
Switzerland00075719
Canada22135417
Czechia34442017
Taiwan13044012
Israel11054011
New Zealand12042110
South Africa0322108
Spain0101428
Austria0003227
Croatia0102126
Norway0221106
Sweden0011136
Bulgaria1310005
Greece1100215
Georgia1210004
Hong Kong2101004
Netherlands0002024
Serbia1210004
Slovakia2000024
Argentina1101003
Malaysia0210003
Ireland0000112
Portugal0100102
Mexico1000001
Singapore0100001
08

Study locations

343 sites
  • Digestive Health Specialists of the Southeast
    Dothan, Alabama 36305, United States
  • Mayo Clinic Arizona
    Scottsdale, Arizona 85259, United States
  • VA Long Beach Healthcare System
    Long Beach, California 90822, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • South Denver Gastroenterology, PC
    Lone Tree, Colorado 80124, United States
  • Connecticut GI PC-Research Division
    Farmington, Connecticut 06032, United States
  • UF Health at Shands Hospital
    Gainesville, Florida 32610, United States
  • Florida Research Institute
    Lakewood Ranch, Florida 34211, United States
  • University of Miami Crohn's and Colitis Center
    Miami, Florida 33136, United States
  • Cordova Research Institute
    Miami, Florida 33155, United States
  • Gastroenterology Group of Naples
    Naples, Florida 34102, United States
  • Advanced Medical Research Center
    Port Orange, Florida 32127, United States
  • Tampa General Hospital
    Tampa, Florida 33606, United States
  • Shafran Gastroenterology Center
    Winter Park, Florida 32789, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33540, United States
  • Gastroenterology Associates of Central Georgia, LLC
    Macon, Georgia 31201, United States
  • Gastrointestinal Specialists of Georgia
    Marietta, Georgia 30060, United States
  • Atlanta Gastroenterology Specialist, PC
    Suwanee, Georgia 30024, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • University of Louisville, Clinical Trials Unit
    Louisville, Kentucky 40202, United States
  • Delta Research Partners, LLC
    Monroe, Louisiana 71201, United States
  • Louisiana Research Center, LLC
    Shreveport, Louisiana 71105, United States
  • Investigative Clinical Research
    Annapolis, Maryland 21401, United States
  • MGG Group Co., Inc., Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Gastro Center of Maryland
    Columbia, Maryland 21045, United States
  • Meritus Center for Clinical Research
    Hagerstown, Maryland 21742, United States
  • Massachusetts General Hospital - Crohn's and Colitis Center
    Boston, Massachusetts 02114, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48047, United States
  • Center for Digestive Health
    Troy, Michigan 48098, United States
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
  • Kansas City Research Institute
    Kansas City, Missouri 64131, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • NY Scientific
    Brooklyn, New York 11235, United States
  • NYU Langone Long Island Clinical Research Associates
    Great Neck, New York 11021, United States
  • Carolina's GI Research, LLC
    Raleigh, North Carolina 27607, United States
  • Fargo Gastroenterology and Hepatology Clinic
    Fargo, North Dakota 58103, United States
  • Consultants for Clinical Research
    Cincinnati, Ohio 45219, United States
  • UC Health Physicians Clifton
    Cincinnati, Ohio 45219, United States
  • Great Lakes Gastroenterology Research, LLC
    Mentor, Ohio 44060, United States
  • Gastroenterology Associates of Orangeburg
    Orangeburg, South Carolina 29118, United States
  • Rapid City Medical Center
    Rapid City, South Dakota 57701, United States
  • WR-ClinSearch, LLC
    Chattanooga, Tennessee 37421, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Quality Medical Research
    Nashville, Tennessee 37211, United States
  • Vanderbilt University Medical Center - IBD Clinic
    Nashville, Tennessee 37212-1375, United States
  • San Antonio Military Medical Center
    Fort Sam Houston, Texas 78219, United States
  • DHAT Research Institute
    Garland, Texas 75044, United States
  • Baylor College of Medicine- Baylor Medical Center
    Houston, Texas 77030, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Clinical Associates in Research Therapeutics of America, LLC
    San Antonio, Texas 78212, United States
  • Gastroenterology Research of San Antonio
    San Antonio, Texas 78229, United States
  • Texas Digestive Disease Consultants
    San Marcos, Texas 78666, United States
  • Texas Digestive Disease Consultants
    Southlake, Texas 76092, United States
  • Spring Gastroenterology
    The Woodlands, Texas 77380, United States
  • HP Clinical Research
    Bountiful, Utah 84010, United States
  • University of Virginia Health System
    Charlottesville, Virginia 22908, United States
  • Gastroenterology Associates Of Tidewater
    Chesapeake, Virginia 23320, United States
  • Emeritas Research Group LLC
    Lansdowne Town Center, Virginia 20176, United States
  • McGuire DVAMC
    Richmond, Virginia 23249, United States
  • University of Wisconsin Hospital & Clinics
    Madison, Wisconsin 53705, United States
  • Allegiance Research Specialists, LLC
    Wauwatosa, Wisconsin 53225, United States
  • Instituto de Investigaciones Clinicas Mar del Plata
    Mar del Plata, B7600FZN, Argentina
  • Instituto Médico Cer
    Quilmes, B1878, Argentina
  • St. Vincent's Hospital Sydney
    Darlinghurst, New South Wales 2010, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2747, Australia
  • Coastal Digestive Health
    Mountain Creek, Queensland 4557, Australia
  • Mater Misericordiae Ltd
    South Brisbane, Queensland 4101, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland 4102, Australia
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Monash Medical Centre
    Clayton, Victoria 3168, Australia
  • Footscray Hospital
    Footscray, Victoria 3011, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Cabrini Hospital
    Malvern, Victoria 3144, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Universitatsklinik Innsbruck
    Innsbruck, 6020, Austria
  • AKH-Medizinische Universitat Wien
    Wien, 1090, Austria
  • GZA Ziekenhuizen campus Sint-Vincentius
    Antwerpen, 2018, Belgium
  • CUB Hopital Erasme
    Brussels, 1070, Belgium
  • Universitair Ziekenhuis Leuven
    Leuven, B-3000, Belgium
  • Centre Hospitalier Chretien (CHC) - Clinique Saint-Joseph
    Liège, 4000, Belgium
  • MHAT Sveti Pantaleymon - Pleven OOD
    Pleven, 5800, Bulgaria
  • "MDHAT Dr. St.Cherkezov" AD
    Veliko Tŭrnovo, 5000, Bulgaria
  • MHAT "Sveta Petka" AD
    Vidin, 3700, Bulgaria
  • University of Calgary, Heritage Medical Research Clinic
    Calgary, Alberta T2N 4Z6, Canada
  • The Gordon and Leslie Diamond Health Care Centre
    Vancouver, British Columbia V5Z 1M9, Canada
  • Hamilton Health Sciences Corporation, McMaster University Medical Centre
    Hamilton, Ontario L8S 4K1, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7N 0W8, Canada
  • Toronto Digestive Disease Associates Inc.
    Vaughan, L4L 4Y7, Canada
  • Clinical Hospital Dubrava
    Zagreb, 10000, Croatia
  • University Hospital Center Zagreb
    Zagreb, 10000, Croatia
  • Hepato-Gastroenterologie HK, s.r.o.
    Hradec Kralove, 500 12, Czechia
  • Oblastni nemocnice Mlada Boleslav, a.s., nemocnice Stredoceskeho kraje, Gastroenterologicke oddeleni
    Mladá Boleslav, 293 01, Czechia
  • G.E.P. Clinic, s r.o.
    Praha 3, 130 00, Czechia
  • ISCARE a.s. (Klinicke centrum ISCARE), Klinicke a vyzkumne centrum pro strevni zanety
    Praha 9, 190 00, Czechia
  • CHU Amiens Picardie
    Amiens, 80054, France
  • CHU de Caen
    Caen, 14033, France
  • CHU de Clermont-Ferrand - Hopital d'Estaing
    Clermont-Ferrand, 63003, France
  • APHP - Hopital Beaujon - Clichy - Universite Paris VII
    Clichy, 92110, France
  • CHU de Dijon Bourgogne - Hopital Francois Mitterand
    Dijon, 21079, France
  • CHU Grenoble Alpes
    La Tronche, 38700, France

Showing the first 100 of 343 sites across 40 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Feagan BG, Danese S, Loftus EV Jr, Vermeire S, Schreiber S, Ritter T, Fogel R, Mehta R, Nijhawan S, Kempinski R, Filip R, Hospodarskyy I, Seidler U, Seibold F, Beales ILP, Kim HJ, McNally J, Yun C, Zhao S, Liu X, Hsueh CH, Tasset C, Besuyen R, Watanabe M, Sandborn WJ, Rogler G, Hibi T, Peyrin-Biroulet L. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021 Jun 19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021 Jun 3. PubMed 34090625 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2016 to primary completion in Mar 2020, 40 months.

Results were first posted in Apr 2021, 1 year after primary completion.

Of 87 industry-sponsored phase 3 interventional studies under Colitis, Ulcerative, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 70. This study's 40 months is below that.

Counting every sponsor, half of 101 studies reached it within 48 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2016
First posted
Sep 26, 2016
StartActual
Nov 14, 2016
Primary completionActual
Mar 31, 2020
CompletionActual
Mar 31, 2020
Results first posted
Apr 21, 2021
Last update
Apr 21, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02914522
Lead sponsor
Gilead Sciences
Collaborators
Galapagos NV
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Nov 14, 2016
Primary completion
Mar 31, 2020
Completion
Mar 31, 2020
Results posted
Apr 21, 2021
Last update
Apr 21, 2021

Study contacts

Gilead Study Director
study director · Gilead Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GLPG0634

Start the discussion